Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.186
-0.040 (-17.65%)
At close: Dec 20, 2024, 4:00 PM
0.190
+0.004 (2.10%)
After-hours: Dec 20, 2024, 7:59 PM EST
Aditxt Revenue
Aditxt had revenue of $6.85K in the quarter ending September 30, 2024, a decrease of -94.49%. This brings the company's revenue in the last twelve months to $212.11K, down -71.70% year-over-year. In the year 2023, Aditxt had annual revenue of $645.18K, down -30.90%.
Revenue (ttm)
$212.11K
Revenue Growth
-71.70%
P/S Ratio
0.05
Revenue / Employee
$4,513
Employees
47
Market Cap
2.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
iCoreConnect | 11.05M |
ReShape Lifesciences | 8.18M |
Petros Pharmaceuticals | 4.02M |
60 Degrees Pharmaceuticals | 462.61K |
Alaunos Therapeutics | 7.00K |
ADTX News
- 9 days ago - Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Business Wire
- 5 weeks ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 6 weeks ago - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Business Wire
- 6 weeks ago - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Business Wire
- 6 weeks ago - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Business Wire
- 6 weeks ago - Evofem Secures Investor Support for Proposed Merger through Voting Agreements - PRNewsWire
- 7 weeks ago - Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - Business Wire
- 7 weeks ago - Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time - Business Wire